In a recent study, it has been shown that TREM2 could be a valuable therapeutic target for the treatment of AD since TREM2 overexpression rescued cognitive impairments in APP/PS1 mice by inhibiting microglia-mediated neuroinflammation (Ruganzu et al., 2021). The gene discussed is APP; the disease is Alzheimer disease.